{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-005614","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.802750+00:00","generated_at":"2026-06-07T00:56:48.487754+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Seres reports preliminary Q4 VOWST net sales of $10.4M; FDA Fast Track for SER-155","bullets":["VOWST Q4 2023 net sales approx $10.4M (unaudited); total 2023 net sales since June launch approx $19.6M.","2,833 patient enrollment forms received and 2,015 new patient starts since launch through year-end 2023.","SER-155 received FDA Fast Track Designation; Phase 1b Cohort 2 data readout expected in Q3 2024.","Preliminary cash, cash equivalents, and investments of approx $128M as of Dec 31, 2023.","Company expects cash plus expected $45M Tranche B from Oaktree to support operations into Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-005614","json":"https://secwatch.observer/filing/0001193125-24-005614.json","markdown":"https://secwatch.observer/filing/0001193125-24-005614.md","text":"https://secwatch.observer/filing/0001193125-24-005614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524005614/0001193125-24-005614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524005614/d129973d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:56:48.487754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1965d1cb0503d460119cc5bc76725aa1446fc74e","claim":"Seres Therapeutics, Inc. reported the fourth quarter of 2023 results: revenue net sales of VOWST of approximately $10.4 million (unaudited).","evidence_excerpt":"On January 9, 2024, Seres Therapeutics, Inc. (the “Company”) issued a press release in which the Company announced, among other things, that based on preliminary financial results, the Company had net sales of VOWST of approximately $10.4 million (unaudited) in the fourth quarter of 2023, and preliminary cash, cash equivalents and investments of approximately $128 million (unaudited) as of December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524005614/0001193125-24-005614-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023"},{"label":"Revenue","value":"net sales of VOWST of approximately $10.4 million (unaudited)"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}